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Abstract
Background: To achieve synthetic control over how a cell responds to other cells or the extracellular environment,
it is important to reliably engineer proteins that can traffic and span the plasma membrane. Using a modular
approach to assemble proteins, we identified the minimum necessary components required to engineer such
membrane-spanning proteins with predictable orientation in mammalian cells.
Results: While a transmembrane domain (TM) fused to the N-terminus of a protein is sufficient to traffic it to the
endoplasmic reticulum (ER), an additional signal peptidase cleavage site downstream of this TM enhanced sorting
out of the ER. Next, a second TM in the synthetic protein helped anchor and accumulate the membrane-spanning
protein on the plasma membrane. The orientation of the components of the synthetic protein were determined
through measuring intracellular Ca2+ signaling using the R-GECO biosensor and through measuring extracellular
quenching of yellow fluorescent protein variants by saturating acidic and salt conditions.
Conclusions: This work forms the basis of engineering novel proteins that span the plasma membrane to
potentially control intracellular responses to extracellular conditions.
Keywords: Transmembrane proteins, Modular assembly, Endoplasmic reticulum, Plasma membrane, Protein
engineering, Synthetic biology
Background
The ability to reliably engineer a protein that spans the
plasma membrane (PM) allows synthetic control over
the communication of the cell with its extracellular
environment [1]. The intercellular and extracellular
environment is separated by the PM, where proteins
spanning the PM facilitate diverse cellular processes
such as signal transduction, cell-cell contact and mo-
lecular transport [2]. Many proteins spanning the PM
contain an N-terminal signal peptide that is recognized
by the signal recognition particle (SRP) and recruited to
the ribosomes on the endoplasmic reticulum (ER) for
translation [3, 4]. Subsequently the signal peptide is
cleaved off by the signal peptidase. Signal peptides are
usually 20 to 60 amino acids consisting of initially, a
hydrophilic segment followed by a hydrophobic segment
and finally a signal peptidase cleavage site [5, 6]. Proteins
spanning the PM require at least one transmembrane do-
main (TM) consisting of mostly hydrophobic residues,
that at first, anchors the protein to the ER membrane,
among other retention signals. Next, the PM-bound
proteins are packaged into coated vesicles (i.e. COP II ves-
icles) and shuttled from the ER to the Golgi apparatus for
further processing [7]. Upon exiting the Golgi apparatus,
they are again packaged into vesicles (i.e. clathrin-coated
vesicles) and shuttled to the PM [7, 8]. After the mem-
brane of the vesicle fuses with the PM, the membrane-
spanning protein is delivered to the PM.
While many groups have created membrane-tethered
proteins for use as research tools and therapeutics [9, 10],
it is unclear what the minimum necessary components to
engineer a protein that spans the PM are. Examples of
membrane-tethered proteins from other groups include
antibody fragments comprising pseudo-receptors to
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activate the immune system [11], secreted cytokines to in-
duce specific antitumor immune responses with reduced
systemic toxicity [12, 13] and enzymes to activate
prodrugs [14]. To enhance cell surface expression of
membrane-tethered proteins, design strategies have fo-
cused on the careful selection of the TM, the cytoplasmic
tail and the extracellular juxtamembrane linker [15].
Elements such as the transmembrane domain and the
cytoplasmic tail of the murine B7-1 antigen and the
hinge-CH2-CH3 region of the human immunoglobulin G
(IgG1) heavy chain have been established to enhance pro-
tein expression on the cell surface [16, 17]. While the
minimum sequences required to target specific proteins
such as the respiratory syncytial virus F protein [18] and
the SNARE protein SNAP-25 [19] have been elucidated in
independent studies previously, these specific minimum
sequences could differ between target proteins.
To determine the minimum necessary components to
engineer a protein that spans the PM with a defined
orientation, we used a modular synthetic biology ap-
proach to assemble the protein. Previously, our group
employed a similar approach to determine that the mini-
mum component to engineer a protein that spans the
ER is a single TM at an arbitrary location in the protein
[20]. An N-terminal signal peptide was not necessary to
deliver the protein to the ER [20]. Here, we confirm that
while an N-terminal TM directs the protein for translation
in the ER, the engineered protein is still strongly retained in
the ER. The addition of a downstream peptidase cleavage
site to this TM further enhances the exit of the engineered
protein from the ER, thereby decreasing its retention in the
ER. Finally, a second TM strongly increases retention of the
engineered protein in the PM. Furthermore, the orientation
(i.e., extracellular vs. intracellular) of the engineered proteins
were determined by fluorescence quenching and detection
of intracellular Ca2+ signaling.
Results and discussion
A signal peptidase cleavage site enhances sorting out of
the ER
While an N-terminal TM traffics the protein to the ER,
an additional signal peptidase cleavage site downstream
of this TM enhanced sorting out of the ER. The protein
named TM-Venus was created as the tandem fusion of
the TM from the human toll-like receptor 4
(632TIIGVSVLSVLVVSVVAVLVY652) (TM) and the yel-
low fluorescent protein (YFP) mutant Venus [21]
(Fig. 1a,b). Although the TM domain from TLR4 was
used in this study, TM domains from other proteins
should behave similarly because in our previous work
[20], the TM domain from platelet-derived growth factor
receptor behaved indistinguishably to TLR4. To label the
plasma membrane, the protein Lyn-Ceru was used con-
sisting of the tandem fusion of N-terminal localization
sequence of Lyn kinase (1MGCIKSKGKDSA12) and the
cyan fluorescent protein variant Cerulean [22]. Following
post-translational modification (i.e. palmitoylation of the
cysteine amino acid), Lyn-Ceru localizes to the cytoplas-
mic side of the plasma membrane. Likewise, to label the
ER, the protein STIM1-mRFP was used, consisting of the
tandem fusion of the stromal interaction molecule 1
(STIM1, an endogenous ER-Ca2+ sensor labeling the ER
membrane [23]) and the monomeric red fluorescent pro-
tein (mRFP) [24]. Mammalian cells were co-transfected
with TM-Venus and Lyn-Ceru to compare localization
with the PM or TM-Venus and STIM1-mRFP to compare
localization with the ER (Fig. 1c-g). TM-Venus showed a
web-like fluorescence distribution similar to STIM1-
mRFP as would be expected from ER localization
(Pearson’s correlation coefficient (PCC) = 0.87 ± 0.01)
(Table 1, Fig. 1f-g) (n = 3 experiments, with at least 9 cells
per experiment). In contrast, the TM-Venus had a starkly
different fluorescence distribution compared to Lyn-Ceru
that labels the plasma membrane (Table 1, PCC = 0.75 ±
0.04). There was a significant difference between ER and
plasma membrane localization (p < 0.01). Notably, Lyn-
Ceru labels the PM distinctly depending on cell spreading.
Cells that spread well (e.g. COS-7 cells) show a matte-like
fluorescence appearance, whereas cells that do not spread
as well (e.g. CHO cells (Additional file 1: Figure S1)) often
exhibit a fluorescence that outlines the boundary of the
cell (Fig. 1c-e). To enhance sorting out of the ER, the pro-
tein named TLP-Venus was created as the tandem fusion
of TM, the signal peptidase cleavage site from human
immunoglobulin K (16PGSTGD21) and Venus. Cells were
co-transfected with TLP-Venus and either Lyn-Ceru or
STIM1-mRFP. TLP-Venus had a less web-like fluores-
cence distribution when compared to STIM1-mRFP
(PCC = 0.80 ± 0.10) (Table 1, Fig. 1h-l) (n = 3 experiments,
with at least 9 cells per experiment) and while it did not
look plasma membrane when measured against Lyn-Ceru
(Table 1, PCC = 0.83 ± 0.05) either, it improved sorting
compared to the TM-Venus case (Fig. 1d,i) (n = 3 experi-
ments, with at least 9 cells per experiment). Repeated trials
in another mammalian cell line (i.e. CHO cells) yielded simi-
lar results (Additional file 1: Figure S1 a-j) (n = 3 experi-
ments, with at least 9 cells per experiment). Thus, the signal
peptidase cleavage site enhanced sorting out of the ER.
A second TM anchors the protein on the PM
While TLP-Venus enhances sorting out of the ER, a sec-
ond TM helps anchor and accumulate proteins on the
PM (Fig. 2a). To anchor proteins on the plasma mem-
brane, the construct TLP-Venus-TM was created. Pro-
teins sorted from the ER are directed via COP II vesicles
to the trans Golgi network (TGN) for further processing
before being packaged into recycling endosomes (RE) or
post-Golgi transport intermediates (PGTIs) for delivery
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to the plasma membrane [3, 7, 25]. From the TGN, pro-
teins are committed to one of two secretory pathways:
constitutive secretion involves the continuous release of
proteins from the cell whereas regulated secretion re-
tains proteins intracellularly before an external signal
initiates release [3]. Ultimately, the secretory vesicle
fuses with the PM and the protein is either to be se-
creted or retained on the plasma membrane [26, 27]. It
is plausible that the presence of an anchoring domain
(e.g. TM) on the protein will enhance retention of the
protein on the PM. In theory, since the TLP contains a
signal peptidase cleavage site, the first TM within TLP
cannot serve as permanent anchoring domain, however
the second TM can serve in that function. When TLP-
Venus-TM was co-transfected with either Lyn-Ceru
(PCC = 0.96 ± 0.001) or STIM1-mRFP (PCC = 0.64 ±
0.10) (Table 1) in COS-7 cells, the protein distribution
skewed more towards the plasma membrane as expected
(Fig. 2b-g) (n = 3 experiments, with at least 9 cells per
experiment). The matte-like fluorescence was signifi-
cantly similar to that of Lyn-Ceru unlike the web-like
detail seen in STIM1-mRFP (p < 0.01, Fig. 2c,f ) (n = 3 ex-
periments, with at least 9 cells per experiment). Re-
peated trials in another mammalian cell line (i.e. CHO)
Fig. 1 A signal peptidase cleavage site enhances sorting out of the ER. Schematic layout of fusion proteins constructed in the study (a). Pictorial
representation of receptors exiting the ER (b). COS-7 cells transfected with the plasma membrane labelled Lyn-Ceru showed a matte-like appearance (c) while
those transfected with the ER labelled STIM1-mRFP showed a web-like fluorescence distribution (f inset). TM-Venus showed a web-like
fluorescence distribution similar to STIM1-mRFP (d and f). Merged images illustrate resultant co-localization (e and g). COS-7 cells transfected with TLP-
Venus (containing an additional signal peptidase cleavage site) had a less web-like fluorescence distribution when compared to STIM1-mRFP (h, i and
k). Merged images illustrate resultant co-localization (j and l). Amino acid single letter codes PGSTGD represent proline, glycine, serine, threonine,
glycine and aspartic acid, respectively. TM: transmembrane domain TLR4, TLP: fusion of TM with signal peptidase cleavage site from human immunoglobulin
K, RGECO: red fluorescent genetically encoded Ca2+ indicator, ER: endoplasmic reticulum, LC: Lyn-Ceru, STIM1: stromal interaction molecule 1. Scale bars are
10 μm. Images are false colored: CFP, cyan; YFP, green; mRFP, red. All insets show zoomed regions (4x) of structures in dotted rectangles. All experiments were
repeated at least 3 times
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yielded similar results (Additional file 1: Figure S1 k-o)
(n = 3 experiments, with at least 9 cells per experiment).
To estimate the relative degree of PM accumulation be-
tween TM-Venus, TLP-Venus and TLP-Venus-TM, we
compared their co-localization to STIM1-mRFP and
Lyn-Ceru in the same cell (Table 1). If the co-
localization is the same as STIM1-mRFP, the ratio of PM
accumulation is 0; if similar to Lyn-Ceru, 1. The ratio of
PM accumulation for TM-Venus, TLP-Venus and TLP-
Venus-TM was calculated as 0.57, 0.71, and 0.93, re-
spectively, suggesting each modification increased accu-
mulation to the PM.
To compare the rate of trafficking of TM-Venus, TLP-
Venus and STIM1-mRFP to the PM, we performed a
cyclohexamide chase assay in CHO cells. Since cyclo-
hexamide inhibits protein synthesis, we can determine
protein accumulation on the PM over time by observing
the co-localization with Lyn-Ceru. At time 0 h, both TM-
Venus and STIM1-mRFP had lower and similar PCC with
Lyn-Ceru (PCC = ~0.43 ± 0.20) whereas TLP-Venus had a
higher and statistically different PCC with Lyn-Ceru (PCC
= 0.69 ± 0.13) (Additional file 2: Figure S2). At time 1, 4
and 12 h, cyclohexamide enhanced accumulation of both
TM-Venus, TLP-Venus to the PM at a similar rate, but as
expected did not enhance accumulation of STIM1-mRFP
to the PM (Additional file 2: Figure S2). It is worth noting
that in our previous study [20], we created proteins of the
TM-fluorescent protein-TM architecture where the fluor-
escence was mostly ER, so the signal cleavage site is
needed for enhanced exiting of the ER.
Venus faces the extracellular side in the TLP-Venus-TM
construct
To determine the orientation of TLP-Venus-TM, fluores-
cence quenching was performed using saturating acidic
and salt conditions. Under saturated acidic conditions,
rapid (<1 ms) protonation of the protein backbone
physically expands and thus denatures the barrel-like do-
main housing fluorescence-producing chromophore phe-
nols. This makes the chromophores also susceptible to
protonation leading to a decrease in fluorescence [28, 29].
Fluorescence quenching is also seen with an increased salt
concentration which reduces the repulsion between surface
charges on the protein causing it to collapse via van der
Waals forces [30]. Since transport through ion channels is
often needed to influx these stimuli (i.e. H+, Na+, Cl−), they
do not freely permeate the hydrophobic PM bilayer due to
charge constraints. Within a minute of treatment with ei-
ther [30 μM]f of HCl or [60 μM]f of NaCl, a change in the
expected fluorescence distribution of TLP-Venus- TM was
observed (Fig. 2h-o) (n = 9) (n = 3 experiments, with at least
9 cells per experiment). Noticeably, only the plasma mem-
brane localized protein (i.e. Venus facing extracellularly)
was quenched as it was accessible to the quenching agents
while those proteins being processed intracellularly
remained intact. At time = 0, the fluorescence appears
strongly matte-like while within a minute post treatment,
this trait vanishes and a previously masked fluorescence of
the intracellular proteins being processed becomes clearly
visible. Since the fluorescence distribution of Lyn-Ceru
which is facing the cytoplasmic side of the PM remains
identical pre- and post-treatment, Venus in the TLP-
Venus-TM construct should be extracellular (Fig. 2h, j, l, n)
(n = 3 experiments, with at least 9 cells per experiment).
An ancillary fragment, R-GECO faces the cytoplasmic side
in the TLP-Venus-TM-R-GECO
A protein domain fused C-terminal to TLP-Venus-TM
faces the cytoplasm. To determine the orientation of this
domain, the construct TLP-Venus-TM-R-GECO was
created, where R-GECO is a red fluorescent genetically
encoded Ca2+ indicator [27] (Fig. 3a). The extracellular
Ca2+ concentration in the media is approximately 2 mM
while the intracellular concentration ranges from 0.1 to
1 μM - a difference of a thousand times. R-GECO being
sensitive to the smaller range would not be responsive to
any intracellular Ca2+ transient if it were facing extracel-
lularly [28]. Co-transfection of TLP-Venus-TM-RGECO
and Lyn-Ceru in mammalian cells confirmed its
localization to the plasma membrane as indicated by the
cell’s matte-like appearance (PCC = 0.83 ± 0.09) (Fig. 3b-g)
(n = 3 experiments, with at least 9 cells per experiment).
The red fluorescence from R-GECO was initially weak but
increased in intensity in response to a Ca2+ transient.
Upon stimulation with 10 μM ATP, the Ca2+ concentra-
tion rapidly increased to a peak within a few seconds and
then gradually declined to its basal level within two to
three minutes (Fig. 3h) (n = 3 experiments, with at least 9
cells per experiment). It has been established that ATP
activates endogenous P2Y receptors in cells to stimulate
IP3 production and subsequent Ca
2+ release from the
Table 1 Ratios of Pearson’s correlation coefficient (PCC) of fusion





TM-Venus x 0.75 ± 0.04 0.57
x 0.87 ± 0.01
TLP-Venus x 0.83 ± 0.05 0.71
x 0.80 ± 0.10
TLP-V-TM x 0.96 ± 0.001 0.93
x 0.64 ± 0.10
PCCs of fusion proteins with markers LC (Lyn-Ceru) and STIM1 localized to the
PM and ER, respectively
aAverage PCCs calculated from 3 independent experiments with at least 3 cells
per experiment
bRatio of PM accumulation calculated as: ¼ Ratio LC:fusion proteinð Þ−Ratio LC:STIM1ð ÞRatio LC:LCð Þ−Ratio LC:STIM1ð Þ ;
where Ratio (LC:STIM1) = 0.42 and Ratio (LC:LC) = 1
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endoplasmic reticulum [29]. The measured Ca2+ response
shows that the domain following the TM was intracellular.
Conclusions
Using a modular synthetic biology approach to assemble
proteins, we verify that proteins are targeted to the ER
membrane with the inclusion of an N-terminal TM. With
the addition of a peptidase cleavage site downstream of
the TM, the protein has enhanced exit from the ER; with
the further addition of a second TM, the protein can effi-
ciently anchor and accumulate on the PM. Furthermore,
fluorescence quenching and intracellular Ca2+ responses
were used to distinguish domain orientation. This study
establishes a foundation to engineer novel synthetic pro-
teins that span the PM that can be used to potentially dir-
ect intracellular signaling in response to changing
extracellular conditions. For instance, extracellular do-
mains could be selected to dimerize in response to a syn-
thetic molecule, which in turn cause specific intracellular




STIM1-mRFP, Lyn-Ceru and TMTLR4 were subcloned
previously [20, 31]. TLP was created by fusing the
Fig. 2 An additional transmembrane domain anchors proteins on the PM with the fluorescent protein, Venus, facing extracellularly. Pictorial
representation of receptor anchoring and orientation (a). COS-7 cells transfected with the plasma membrane labelled Lyn-Ceru showed a matte-like
appearance (b and c) while those transfected with the ER labelled STIM1-mRFP showed a web-like fluorescence distribution (e and f). Merged images
illustrate resultant co-localization (d and g). TLP-V-TM skewed more towards a matte-like plasma membrane appearance (b and c). Fluorescence
quenching with [30 μM]f HCl showed no effect on membrane-labelled Lyn-Ceru at time = 0 and time = 1 min (h and i) but did sequester Venus (j and
k). Likewise, fluorescence quenching with [60 μM]f NaCl showed no effect on membrane-labelled Lyn-Ceru at time = 0 and time = 1 min (l and m) but
again sequestered Venus (n and o). ER: endoplasmic reticulum, PM: plasma membrane, hv: emitted fluorescent light, HCl: hydrogen chloride, NaCl:
sodium chloride, TM: transmembrane domain TLR4, TLP: fusion of TM with signal peptidase cleavage site from human immunoglobulin K, V: Venus
fluorescent protein, LC: Lyn-Ceru, STIM1: stromal interaction molecule 1. Scale bars are 10 μm. Images are false colored: CFP, cyan; YFP, green; mRFP,
red. All insets show zoomed regions (4x) of structures in dotted rectangles. All experiments were repeated at least 3 times
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transmembrane domain (TMTLR4) with signal peptidase
cleavage site from human immunoglobulin K
(16PGSTGD21) through overlap PCR and insertion into
the pCfvtx3 [31, 32]. All subsequent fusion proteins with
the yellow fluorescent protein (YFP) mutant Venus and
the monomeric red fluorescent protein (mRFP) were
subcloned as previously described [32–34]. The frag-
ment R-GECO was amplified from CMV-NLS-R-GECO,
which was a gift from Robert Campbell (Addgene plas-
mid #32462) and inserted into our cassette subcloning
methodology. All plasmids were transformed in Escheri-
chia coli and were isolated using the Mini-prep kit
(Invitrogen).
Cell culture and transfection
COS-7 and CHO cells were maintained in Dulbecco’s
Modified Eagle’s Medium containing 25 mM D-glucose,
1 mM sodium pyruvate and 4 mM L-glutamine (Invitro-
gen, Carlsbad, CA) with 10% supplemented Fetal Bovine
Serum (FBS) (Sigma Aldrich, St. Lois, MO) in T25 flasks
Fig. 3 An ancillary fragment, R-GECO, is cytoplasmic and responsive to an induced Ca2+ influx. Pictorial representation of receptor orientation and
response (a). COS-7 cells transfected with the plasma membrane labelled Lyn-Ceru showed a matte-like appearance (b and c) while those transfected
with the ER labelled STIM1-mRFP showed a web-like fluorescence distribution (e and f). TLP-V-TM-RGECO showed a matte-like fluorescence distribution
similar to Lyn-Ceru (b and c). Merged images illustrate resultant co-localization (d and g). Upon stimulation with 10 μM ATP, the Ca2+ concentration
rapidly increased to a peak within a few minutes and then gradually declined to its basal level within two to three minutes (h). ER: endoplasmic
reticulum, PM: plasma membrane, ATP: adenosine triphosphate, TM: transmembrane domain TLR4, TLP: fusion of TM with signal peptidase cleavage
site from human immunoglobulin K, V: Venus fluorescent protein, RGECO: red fluorescent genetically encoded Ca2+ indicator, LC: Lyn-Ceru, STIM1:
stromal interaction molecule 1. Scale bars are 10 μm. Images are false colored: CFP, cyan; YFP, green; mRFP, red. All insets show zoomed regions (4x) of
structures in dotted rectangles. All experiments were repeated at least 3 times
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(37 °C and 5% CO2). Cells were passaged at 95% con-
fluency using 0.05% TrypLE with Phenol Red
(Invitrogen) and seeded onto 24-well Multiwell Plates
(Falcon, Corning, NY) at a dilution of 1:20. Cells were
transiently transfected using Lipofectamine 2000 accord-
ing to manufacturer’s protocols (Invitrogen). Post-
transfection, cells were treated with 0.05% TrypLE with
Phenol Red (Invitrogen) and plated in 96-well tissue cul-
ture plates (Sarstedt, Numbrecht, Germany) at a dilution
of 1:4 for imaging.
Quantitative cyclohexamide chase assay
Twenty-four hours post-transfection, CHO cells were in-
cubated with 10 μg/mL of cyclohexamide (Sigma Al-
drich, St. Lois, MO) and imaged after 1, 4 and 12 h.
Results were quantified with one-tailed two-sample Stu-
dent’s t-test between the time points and significance
was reported.
Illumination and imaging
Imaging was performed using an inverted IX81 micro-
scope with Lambda DG4 xenon lamp source and Tuscen
H674-ICE CCD camera with a 40x objective (Olympus).
Filter excitation (EX) and emission (EM) bandpass specifi-
cations were as follows (in nm): CFP (EX: 438/24, EM:
482/32), YFP (EX: 500/24, EM: 542/27), RFP (EX: 580/20,
EM: 630/60) (Semrock). Image acquisition and analysis
was done with ImageJ and μManager software [35, 36].
Co-localization analysis
Colocalization coefficients such as Pearson’s correlation
coefficient (PCC) singly and in conjunction with Costes’
thresholding and Van Steensel’s cross correlation coeffi-
cients (CCF) analysis were calculated using the JaCoP
plugin for ImageJ [37]. Only PCCs were cited as there
were no significant differences between the various cal-
culation methods.
Statistical analysis
For all experiments, mean PCC± standard deviation is cited.
Let the combination of plasmids be termed as follows: TM-
V+ LC=A, TM-V+ STIM1=B, TLP-V + LC=C, TLP-V +
STIM1=D, TLP-V- TM+LC=E, TLP-V- TM+STIM1= F,
TLP-V-TM-RGECO+LC=G, TLP-V-TM-RGECO+STI-
Mek1 =H. A two-tailed two-sample Student’s t-test was per-
formed under the following null hypotheses: H0: μA = μB,
μC = μD, μE = μF, μG = μH, μE = μG and μF = μH. A one-tailed
two-sample t test was performed under the following alter-
native hypotheses: HA: μA < μC, μB > μD, μE > μA, μE > μC, μF
< μB, μF < μD, μG > μA, μG > μC, μH < μB and μH < μD. Only
significant results were cited as p = significance.
Additional files
Additional file 1: Figure S1. Fluorescence images of CHO cells transfected
with the plasma membrane labelled Lyn-Ceru and ER labelled STIM1-mRFP
markers. CHO cells transfected with the plasma membrane labelled Lyn-Ceru
showed a matte-like appearance (a, f and k) while those transfected with the ER
labelled STIM1-mRFP showed a web-like fluorescence distribution (d, i and n).
TM-Venus (b), TLP-Venus (g) or TLP-V-TM (l) peptides show a shift in
fluorescence distribution from a wholly ER (b) to a slight (g) and then an
entirely membrane appearance (l). Merged images illustrate resultant co-
localization (c, e, h, j, m and o). TM: transmembrane domain TLR4, TLP:
fusion of TM with signal peptidase cleavage site from human immunoglobulin
K, V: Venus fluorescent protein, LC: Lyn-Ceru, STIM1: stromal interaction molecule
1. Scale bars are 10 μm. Images are false colored: CFP, cyan; YFP, green; mRFP,
red. All insets show zoomed regions (4x) of structures in dotted rectangles. All
experiments were repeated at least 3 times. (PDF 9198 kb)
Additional file 2: Figure S2. Line graph showing changes in distribution
of plasma membrane labelled Lyn-Ceru compared with ER-labelled STIM1-
mRFP, TM-Venus and TLP-Venus in CHO cells, post cyclohexamide treatment.
CHO cells transfected with the plasma membrane labelled Lyn-Ceru and the ER
labelled STIM1-mRFP, TM-Venus or TLP-Venus. Cells were imaged initially and
after 1, 4 and 12 h after incubation with 10 μg/mL cyclohexamide. Y-axis
shows PCC of the STIM1-mRFP, TM-Venus or TLP-Venus with Lyn-Ceru. TM:
transmembrane domain TLR4, TLP: fusion of TM with signal peptidase
cleavage site from human immunoglobulin K, V: Venus fluorescent protein,
LC: Lyn-Ceru, STIM1: stromal interaction molecule 1. Error bars indicate s.d.
Star indicates significance of p < 0.05. (PDF 238 kb)
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